VAP

Semicarbazide-sensitive amine oxidase (SSAO; EC 1.4.3.21) is an enzyme predominantly located in the endothelium and leukocytes. SSAO is unique among other endothelial-expressed adhesins as it is also an ectoenzyme. A soluble form of SSAO is present in plasma and is known as vascular adhesion protein VAP-1. It is well known to regulate two key inflammatory processes which are integral to progressive renal pathology. Besides causing oxidative stress by its oxidation products, SSAO mediates the transmigration of intraluminal leukocytes into sites of tissue inflammation, which is initially a protective reparative process, but if persistent, can lead to chronic inflammatory cell accumulation[1]. Activation of VAP-1 has been implicated in several pathologies, such as: atherosclerosis, diabetes, Alzheimer's disease, kidney fibrosis, and pulmonary diseases[2].


[1] M Wong et al. Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model. Am J Physiol Renal Physiol. 2014 Oct 15;307(8):F908-16.
[2] T Valente et al. SSAO/VAP-1 protein expression during mouse embryonic development. Dev Dyn. 2008 Sep;237(9):2585-93.

1 Item(s)

per page
Axon ID Name Description From price
2583 PXS 4728A Potent inhibitor of VAP-1/SSAO inhibiting neutrophil rolling and tethering €145.00

1 Item(s)

per page
Please wait...